Gilead Sciences, Inc. $GILD Shares Sold by Capital International Inc. CA

Capital International Inc. CA trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 322,996 shares of the biopharmaceutical company’s stock after selling 34,883 shares during the period. Capital International Inc. CA’s holdings in Gilead Sciences were worth $39,645,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $28,000. Financial Consulate Inc. increased its holdings in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. boosted its position in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares during the last quarter. BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the 4th quarter valued at about $31,000. Finally, Godfrey Financial Associates Inc. purchased a new position in Gilead Sciences in the 4th quarter valued at about $34,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,000 shares of company stock worth $9,047,570 in the last quarter. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 0.0%

Gilead Sciences stock opened at $129.16 on Friday. The company has a 50 day moving average price of $134.38 and a 200 day moving average price of $134.31. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market capitalization of $160.36 billion, a price-to-earnings ratio of 17.60 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on GILD shares. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Citigroup raised their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Argus raised their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.